Article
San Francisco-Despite a settlement by TAP Pharmaceuticals last fall on charges concerning fraudulent pricing and marketing of leuprolide acetate (Lupron)
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
Subcutaneous nivolumab approved in EU, Canada for solid tumors
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test
Combination therapy linked to longer OS vs ADT in veterans with mHSPC